Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cann Group ( (AU:CAN) ) just unveiled an announcement.
Cann Group Limited has reported changes in directors’ interests, lodging Appendix 3Y notices for CEO and Managing Director Jenni Pilcher and director Mike Ryan. The filing discloses that Pilcher has acquired 4,347,826 quoted options in the company, with no consideration payable and no securities disposed, signalling an adjustment to the leadership’s equity exposure that may further align management incentives with shareholder outcomes.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited is an Australian medicinal cannabis company focused on developing, producing and supplying innovative cannabis medicines. Headquartered in Melbourne, it operates a large-scale, state-of-the-art cultivation and GMP manufacturing facility near Mildura, Victoria. The company offers a range of dried flower and oil products, active pharmaceutical ingredients and extracts to customers in Australia and internationally, and also owns Satipharm with its patent-protected cannabis capsule technology.
Average Trading Volume: 5,287,410
Technical Sentiment Signal: Sell
Current Market Cap: A$14M
For an in-depth examination of CAN stock, go to TipRanks’ Overview page.